The US company Immusoft has dosed the first subject with its investigational engineered B cell therapy, ISP-001, in a human Phase I clinical trial of mucopolysaccharidosis type I (MPS I).
Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.
![[Translate to English:]](/fileadmin/_processed_/8/8/csm_MDC_neu_web_fcfe745015.jpg "[Translate to English:]")
![[Translate to English:]](/fileadmin/_processed_/8/9/csm_Logo_MDC_8c2cf30ed2.png "[Translate to English:]"){kind=logo}